BDPTOTCPharmaceutical PreparationsFiscal year ends December 31
BIOADAPTIVES, INC.
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 19, 2026
$0.00−0.00 (-5.56%)
Close on Oct 19, 2026
- Market cap
- $478.03K
- P/E (TTM)
- –
- Dividend yield
- –
Bioadaptives statistics
Financials through Jun 30, 2026, price as of Oct 19, 2026, median of Pharmaceutical Preparations companies for comparison
Valuation
| Measure | Bioadaptives | Industry median |
|---|---|---|
| Market Cap | $334.78K | $197.05M |
| Enterprise Value | $305.55K | $106.56M |
| PS Ratio | 13.10 | 3.93 |
Enterprise value
| Measure | Bioadaptives | Industry median |
|---|---|---|
| EV / Sales | 11.95 | 2.69 |
Income (trailing twelve months)
| Measure | Bioadaptives | Industry median |
|---|---|---|
| Revenue | $25.56K | $57.94M |
| Gross Profit | $19.79K | $90.47M |
| Operating Income | -$909.20K | -$21.44M |
| Pretax Income | -$1.16M | -$14.45M |
| Net Income | -$1.16M | -$22.46M |
| EBITDA | -$909.20K | -$16.91M |
| EPS (Diluted) | -$0.12 | -$0.83 |
Margins
| Measure | Bioadaptives | Industry median |
|---|---|---|
| Gross Margin | 77.4% | 52.3% |
| Operating Margin | -3557.0% | -44.5% |
| Pretax Margin | -4553.2% | -13.0% |
| Profit Margin | -4553.2% | -39.2% |
| EBITDA Margin | -3557.0% | -31.3% |
Returns
| Measure | Bioadaptives | Industry median |
|---|---|---|
| Return on Assets (ROA) | -662.6% | -41.0% |
Growth
| Measure | Bioadaptives | Industry median |
|---|---|---|
| Revenue Growth (YoY) | 694.1% | 6.01% |
| Revenue Growth (3Y CAGR) | 2.09% | 2.25% |
| Revenue Growth (5Y CAGR) | 2.28% | 6.42% |
Balance sheet
| Measure | Bioadaptives | Industry median |
|---|---|---|
| Cash & Short-Term Investments | $29.22K | $62.42M |
| Net Cash (Debt) | $29.22K | $15.68M |
| Net Cash Per Share | $0.00 | $0.65 |
| Equity (Book Value) | -$1.77M | $48.79M |
| Book Value Per Share | -$0.01 | $1.36 |
| Tangible Book Value | -$1.77M | $23.06M |
| Working Capital | -$1.78M | $75.77M |
Financial position
| Measure | Bioadaptives | Industry median |
|---|---|---|
| Current Ratio | 0.04 | 3.30 |
| Quick Ratio | 0.02 | 2.39 |
| Interest Coverage | -3.57 | -7.12 |
Cash flow (trailing twelve months)
| Measure | Bioadaptives | Industry median |
|---|---|---|
| Operating Cash Flow | -$436.36K | -$12.35M |
Efficiency
| Measure | Bioadaptives | Industry median |
|---|---|---|
| Asset Turnover | 0.15 | 0.38 |
| Inventory Turnover | 0.15 | 2.67 |
| Revenue Per Employee | $25.56K | $398.96K |
| Profits Per Employee | -$1.16M | -$732.08K |
| Employee Count | 1 | 73 |
Dividends and yields
| Measure | Bioadaptives | Industry median |
|---|---|---|
| Earnings Yield | -347.6% | -21.2% |
Shares
| Measure | Bioadaptives | Industry median |
|---|---|---|
| Shares Outstanding | 196,927,000 | 59,128,900 |
| Shares Change (YoY) | 759.5% | 11.1% |
| Shares Change (QoQ) | 204.7% | 0.54% |
| Float | 196,802,000 | 48,744,500 |
| Shares Held by Insiders | 0.06% | 11.8% |
Scores
| Measure | Bioadaptives | Industry median |
|---|---|---|
| Altman Z-Score | -254.60 | 0.10 |
| Piotroski F-Score | 3 | 4 |
Calculated by StockData from Bioadaptives's SEC filings and the latest closing price. Hover a measure to see its formula. The grey column is the median of companies in the same industry group (two-digit SIC code); green or red marks a better or worse value than that median.